Kan Chen

Sr. Director DMPK and Clin Pharm @ Dizal Pharma

About

PhD with fifteen years experience in the pharmaceutical industry, ClinPharm and DMPK core team member on projects that span from drug discovery, early and late clinical development. Extensive experience in mass spec imaging, biotransformation, and risk assessment of drug-drug interaction including endogenous biomarker, strategic planning of clinical pharmacology studies towards NDA.

Country

China

City

Shanghai

Industry

Pharmaceuticals

Skill

Drug Discovery, Mass Spectrometry, Analytical Chemistry, In Vivo, Validation, Clinical Trials, Clinical Research, Characterization, Drug Metabolism, Bioanalysis, LC-MS, DMPK, Pharmacokinetics, ADME, HPLC, Chromatography, PK/PD modeling, drug-drug interaction, Pharmacology, Toxicology

Experience

Sr. Director DMPK and Clin Pharm

Dizal Pharmaceutical

2017-11 - Present · 8 yrs 11 mos

上海

Head Of DMPK

AstraZeneca Asia iMed

2017-7 - 2017-11 · 5 mos

Pudongxin District, Shanghai, China

Responsible for preclinical DMPK for drug discovery projects and clinical pharmacology for drug development projects.

Principal Scientist

AstraZeneca Asia iMed

2016-3 - 2017-11 · 1 yr 9 mos

Shanghai City, China

Senior Scientist

AstraZeneca Asia iMed

2010-1 - 2016-3 · 6 yrs 3 mos

Deliver DMPK data package to support clinical trials

Research Fellow

Vanderbilt University Medical Center

2008-11 - 2010-1 · 1 yr 3 mos

Label free mass spec method for Lung cancer biomarker discovery and validation

Service Engineer

Life Technologies

1998-3 - 1998-8 · 6 mos

Provide instrument installation, troubleshooting, customer training from basic to advanced levels

Education

University of New Orleans

Analytical Chemistry

2002 - 2008 · 6 yrs

explore hypoxia induced global proteome changes in zebrafish skeletal muscle tissue Investigate unsual odd-electron fragmentation charaterzation of bioactivated intermediate of xenobiotics in In vitro and In vivo system